November 17, 2022
Carmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, announced that it has gained alignment with U.S. Food and Drug Administration (FDA) on requirements for the evaluation of the Company’s lead product, a Bone Healing Accelerant (BHA) in a second indication, foot and ankle fusion surgery.
Read More
May 11, 2022
Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that Sebastian “Sebby” Borriello joined the company as Chief Business Officer.
Read More
October 7, 2020
Carmell Therapeutics, a pioneering company in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, today announced that Dr. Israel Nur joined the company as a Scientific Advisor.
Read More
April 27, 2020
Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.
Read More
March 20, 2020
Here is the 10 minute presentation by Randy Hubbell, President, CEO & Chairman of the Board.
Read More
January 7, 2020
Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment.
Read More
December 11, 2019
When someone cuts herself and starts to bleed, her platelets aggregate to stop the bleeding. Over time, the body’s enzymes will break down that clot, providing the body’s stem cells with the regenerative factors naturally contained in platelets and plasma.
Read More
August 13, 2019
The medical device industry is facing a generational change in the regulation and validation of its products.
Read More
June 25, 2019
Biologics therapies have the promise to revolutionize orthopedics and sports medicine, but unauthorized operators pose a serious threat to emerging therapies.
Read More
April 11, 2019
In recent months, the U.S. Food and Drug Administration has increased its compliance focus on the regenerative medicine industry, vowing to crack down on illicit stem cell clinics and others advertising the untested use of human cell and tissue-based products (HCT/P), many of which are used in orthopedics.
Read More